AOD-9604 Peptide: Fat-Loss Claims, Human Evidence and Safety Limits
AOD-9604 peptide guide covering HGH fragment biology, animal lipolysis studies, failed human obesity development, FDA compounding concerns and WADA status.
AOD-9604 is a good example of why peptide evidence needs more than a mechanism story. The pitch is simple: take the fat-mobilizing fragment of human growth hormone, leave behind the growth and insulin-resistance liabilities, and use the fragment as a cleaner fat-loss peptide.
That hypothesis produced real preclinical research. It also ran into the hard part of obesity drug development: rodent lipolysis did not translate into a commercially viable human obesity drug. AOD-9604 has been studied in humans, but its development for obesity was terminated after a 24-week trial failed to induce significant weight loss.
That makes AOD-9604 useful to cover, but only with restraint. It is not an approved weight-loss drug, not a GLP-1 alternative, and not a proven stack partner for retatrutide, tirzepatide or semaglutide. Readers comparing peptide claims should also review peptides for weight loss, CJC-1295, tesamorelin and the growth hormone peptide hub.
This guide is educational and not medical advice. AOD-9604 is not an FDA-approved treatment for weight loss, joint disease, body composition or athletic performance. Research-market products can add identity, sterility, impurity and legal risks that clinical papers do not solve.
AOD-9604 At A Glance
| Question | Evidence-aware answer |
|---|---|
| What is it? | A synthetic modified fragment of human growth hormone, often described as Tyr-hGH(177-191). |
| Main marketing claim | Fat loss through lipolysis without full growth hormone effects. |
| Best preclinical evidence | Rodent studies showing reduced weight gain or fat effects in obese models. |
| Human obesity evidence | Early human signals were modest; later development stopped after failed 24-week efficacy results. |
| FDA status | Not FDA approved for any indication covered here. |
| FDA compounding context | FDA flags immunogenicity, peptide-impurity and limited safety-information concerns for compounded AOD-9604. |
| Sport status | WADA prohibits growth hormone fragments including AOD-9604 and hGH 176-191. |
What AOD-9604 Actually Is
AOD-9604 is often called "HGH fragment 176-191" in casual peptide-market language, but the naming is not always precise. PubChem lists AOD-9604 as a defined peptide compound. FDA briefing materials describe AOD-9604 as a hexadecapeptide, a 16-amino-acid synthetic fragment of human growth hormone covering amino acids 177-191 with an additional tyrosine at the N-terminal end.
That distinction matters because product pages often blur AOD-9604, hGH fragment 176-191, full human growth hormone and growth-hormone secretagogues. They are not the same thing. Full recombinant growth hormone is a regulated drug with known endocrine effects. Secretagogues such as CJC-1295, sermorelin and ipamorelin act upstream by changing growth hormone release. AOD-9604 is a short fragment designed around metabolic signaling.
The original idea was appealing: isolate a lipolytic domain of growth hormone without stimulating growth or causing the same diabetogenic profile associated with full growth hormone. The problem is that an appealing design is not the same as proven human weight-loss efficacy.
What The Animal Studies Suggest
The rodent literature is the reason AOD-9604 keeps resurfacing. A 2000 Hormone Research paper studied an oral dose of AOD-9604 in obese Zucker rats. The authors reported reduced body-weight gain and increased lipolytic activity in adipose tissue, without the insulin-sensitivity harm seen with chronic intact growth hormone in that model.
A 2001 Endocrinology study tested human growth hormone and AOD-9604 in obese mice and beta-3 adrenergic receptor knockout mice. In obese mice, AOD-9604 was associated with body-weight and fat effects plus changes in beta-3 adrenergic receptor expression. In knockout mice, the chronic weight and lipolysis effects did not appear in the same way, suggesting beta-3 adrenergic receptor biology was relevant to the mechanism.
Those findings are meaningful preclinical pharmacology. They are not proof that commercial injectable AOD-9604 produces clinically important fat loss in humans. Rodent adipose biology, dose route, energy balance, diet control and trial conditions do not map cleanly onto real-world human use.
What Human Weight-Loss Evidence Shows
The most important human evidence point is not the early positive signal. It is the development failure.
A review in Clinical Pharmacology & Therapeutics summarized the obesity program this way: in a 12-week randomized clinical trial, people receiving AOD-9604 at 1 mg per day lost an average of 2.6 kg compared with 0.8 kg in the placebo group. The same review then notes that AOD-9604 did not produce dose-dependent weight loss, and that development was terminated in 2007 because it failed to induce significant weight loss in a 24-week trial of 536 subjects.
That is the center of the article. AOD-9604 was not abandoned because nobody understood its mechanism. It was abandoned as an obesity drug candidate because the human efficacy signal was not strong enough.
| Evidence layer | What it supports | What it does not support |
|---|---|---|
| Obese rat and mouse studies | AOD-9604 can affect lipolysis and fat biology in controlled animal models. | Predictable human fat loss from peptide-market products. |
| Early human obesity signal | Some modest weight change was reported at one dose in a 12-week trial. | A robust, dose-dependent, approvable obesity effect. |
| 24-week human trial summary | The obesity program failed to show enough efficacy for development. | Claims that AOD-9604 is a proven standalone fat-loss drug. |
| Human safety/tolerability papers | Short-term oral human exposure was studied. | Long-term safety for injectable, compounded or research-market use. |
Why "Lipolysis" Is Not Enough
Lipolysis means breaking stored triglycerides into fatty acids and glycerol. It is a real biological process, but it is often misused in marketing. Mobilizing fat is not the same as losing clinically meaningful body weight.
For sustained weight loss, energy intake, appetite, energy expenditure, nutrient partitioning, compensation, physical activity, medication adherence and tolerability all matter. That is why approved GLP-1 and dual-incretin drugs are not just "fat burners." They change appetite, glycemia, gastric emptying and long-term energy balance in ways that were tested in large human trials.
AOD-9604's mechanism is more peripheral and narrower. That does not mean it has zero biological activity. It means a lipolysis mechanism cannot be treated as a clinical endpoint. The human obesity program is the better evidence anchor.
Cartilage And Joint Claims
AOD-9604 is also marketed for cartilage, osteoarthritis and joint repair. The best-known PubMed-indexed paper here is not a human knee trial. It is a rabbit osteoarthritis model using intra-articular AOD-9604, with or without hyaluronic acid, after collagenase-induced joint injury.
The study reported better gross and histopathologic scores in treated rabbit groups, with combined AOD-9604 and hyaluronic acid performing better than either alone in that model. That is interesting animal evidence. It is not a basis for saying AOD-9604 repairs human cartilage, prevents knee replacement or works as a consumer joint injection.
Any article or clinic page that turns the rabbit model into a human cartilage promise is skipping the clinical trial step.
FDA And Compounding Context
FDA materials are important because AOD-9604 appears in the peptide compounding conversation. FDA's safety-risk page states that compounded drugs containing AOD-9604 may pose significant risk for immunogenicity for certain routes and may involve peptide-related impurity and active pharmaceutical ingredient characterization complexity. FDA also states that it has no, or only limited, safety-related information and lacks sufficient information to know whether the drug would cause harm when administered to humans.
The FDA's AOD-9604 briefing document for the Pharmacy Compounding Advisory Committee also states that AOD-9604 has no applicable USP or National Formulary drug-substance monograph and describes the free base and acetate forms under review.
This does not mean every claim of harm is proven. It does mean the regulatory standard is very different from a marketed research vial or social-media protocol. Compounding and product quality are separate questions from whether a peptide had an early clinical study.
WADA And Athlete Risk
Competitive athletes should treat AOD-9604 as prohibited. WADA's prohibited list names growth hormone fragments including AOD-9604 and hGH 176-191 under the growth hormone section of peptide hormones and releasing factors.
This matters even if a product page calls AOD-9604 "non-hormonal" or says it does not raise IGF-1. Anti-doping rules do not depend on a vendor's marketing category. They depend on the list and on whether the substance or its related biology is prohibited.
How To Evaluate AOD-9604 Claims
Use this filter before trusting AOD-9604 content:
| Claim | Better question |
|---|---|
| "Burns fat without side effects" | Is the source citing human outcomes, or only rodent lipolysis and mechanism? |
| "Works best in a calorie deficit" | Is that a tested AOD-9604 trial result or a way to explain nonspecific fat loss? |
| "No insulin or IGF-1 problems" | Does the source distinguish short-term evidence from long-term safety? |
| "Repairs cartilage" | Is there a human osteoarthritis trial, or only a rabbit model? |
| "Research grade equals clinical grade" | Is identity, sterility, purity and API characterization independently verified? |
| "Athlete friendly" | Has the source checked WADA's current prohibited list? |
Forum reports are useful for discovery. People ask whether AOD-9604 should be stacked with GLP-1 drugs, whether it works only with fasting, why some users feel nothing, and whether it is the same as hGH fragment 176-191. Those reports are uncontrolled anecdotes. The hierarchy should stay: human trials and regulator sources first, animal mechanisms second, anecdotes last.
Bottom Line
AOD-9604 is not a fake molecule, and the preclinical lipolysis story is real enough to explain why it became popular. The problem is clinical translation. The obesity drug program did not show enough human efficacy, and AOD-9604 is not FDA approved for weight loss or joint disease.
The honest summary is that AOD-9604 is a discontinued obesity drug candidate with rodent lipolysis data, modest early human signals, failed later efficacy, FDA compounding concerns and WADA-prohibited status for athletes. It should be read as an evidence cautionary tale, not as a proven fat-loss peptide.
References
PubChem. AOD-9604 compound summary.
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.
Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.
Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.
Valentino MA, et al. Central and peripheral molecular targets for antiobesity pharmacotherapy.
Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.
Cox HD, et al. Detection and in vitro metabolism of AOD9604.
Stier H, et al. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans.
World Anti-Doping Agency. The Prohibited List: growth hormone fragments including AOD-9604 and hGH 176-191.